Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis.
OBJECTIVE
The receptor for advanced glycation end products mediates a variety of inflammatory responses. Soluble receptor for advanced glycation end products has been suggested to function as a decoy abrogating cellular activation. High-mobility group box 1 is a high-affinity binding ligand for the receptor for advanced glycation end products with cytokine activities and plays a role in sepsis.


METHODS
Controlled, in vivo laboratory study.


METHODS
Research laboratory of a health sciences university.


METHODS
C57BL/6 mice.


METHODS
Peritonitis was induced by intraperitoneal injection of Escherichia coli. Mice received soluble receptor for advanced glycation end products or anti-high-mobility group box 1 immunoglobulin G, or the appropriate control treatment.


RESULTS
Soluble receptor for advanced glycation end products-treated mice demonstrated an enhanced bacterial dissemination to liver and lungs, accompanied by increased hepatocellular injury and exaggerated systemic cytokine release, 20 hrs after intraperitoneal administration of Escherichia coli. Soluble receptor for advanced glycation end products administration in healthy, uninfected mice did not induce an immune response. Remarkably, lung inflammation was unaffected. Furthermore, high-mobility group box 1 release was enhanced during peritonitis and anti-high-mobility group box 1 treatment was associated with higher bacterial loads in liver and lungs.


CONCLUSIONS
These data are the first to suggest that receptor for advanced glycation end products ligands, including high-mobility group box 1, limit bacterial dissemination during Gram-negative sepsis.
van Zoelen
Marieke A D
MA
Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. M.A.D.vanZoelen@umcutrecht.nl
Achouiti
Ahmed
A
Schmidt
Ann-Marie
AM
Yang
Huan
H
Florquin
Sandrine
S
Tracey
Kevin J
KJ
van der Poll
Tom
T
D000818:Animals; D018925:Chemokines / Q000378:metabolism; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D005260:Female; D024243:HMGB1 Protein / Q000008:administration & dosage / Q000502:physiology*; D007113:Immunity, Innate / Q000502:physiology*; D007263:Infusions, Parenteral; D008024:Ligands; D008099:Liver / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D008168:Lung / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D020556:Neutrophil Infiltration; D010538:Peritonitis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000008:administration & dosage / Q000276:immunology*; D018805:Sepsis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
D018925:Chemokines; D024243:HMGB1 Protein; D008024:Ligands; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic
FASEB J. 2009 Jun;23(6):1766-74
19164451
Nat Med. 2000 Jun;6(6):643-51
10835680
Shock. 2009 Mar;31(3):280-4
19218854
J Immunol. 2006 Mar 15;176(6):3735-41
16517742
Pediatr Res. 2002 Aug;52(2):148-54
12149489
J Immunol. 2001 May 15;166(10):6323-31
11342656
J Immunol. 2002 Apr 1;168(7):3507-11
11907112
Nat Rev Drug Discov. 2005 Oct;4(10):854-65
16224456
J Exp Med. 2005 Apr 4;201(7):1135-43
15795240
Biochim Biophys Acta. 2000 Dec 20;1498(2-3):99-111
11108954
J Biol Chem. 2004 Feb 13;279(7):5059-65
14617629
J Biol Chem. 1999 Jul 9;274(28):19919-24
10391939
Blood. 2004 Mar 1;103(5):1702-9
14592828
FEBS Lett. 2003 Oct 9;553(1-2):11-7
14550538
Genes Immun. 2002 May;3(3):123-35
12070776
Crit Care. 2007;11(6):R122
18042296
Science. 1999 Jul 9;285(5425):248-51
10398600
J Exp Med. 2006 Jul 10;203(7):1637-42
16818669
Hepatology. 2004 Feb;39(2):422-32
14767995
Nat Med. 1998 Sep;4(9):1025-31
9734395
Adv Immunol. 2004;84:181-200
15246253
Cell. 1999 Jun 25;97(7):889-901
10399917
Nat Med. 2003 Mar;9(3):287-93
12598893
Rheum Dis Clin North Am. 2004 Aug;30(3):627-37, xi
15261345
J Exp Med. 2005 Feb 7;201(3):473-84
15699076
Infect Immun. 1997 Sep;65(9):3847-51
9284162
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301
14695889
Cardiovasc Diabetol. 2007 Mar 07;6:9
17343760
Clin Infect Dis. 1994 Jul;19(1):100-16
7948510
Diabetes. 2001 Dec;50(12):2792-808
11723063
Mol Cell Biol. 2004 Jun;24(11):4880-94
15143181
J Immunol. 2006 Jul 15;177(2):1189-96
16818777
J Infect Dis. 2004 Jun 15;189(12):2308-17
15181580
J Clin Invest. 2004 Jun;113(11):1641-50
15173891
J Infect Dis. 2005 Jun 15;191(12):2138-48
15898001
Nature. 1996 Aug 22;382(6593):685-91
8751438
Am J Pathol. 2001 Aug;159(2):513-25
11485910
Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):407-13
11856825
J Gastroenterol Hepatol. 2006 Apr;21(4):682-8
16677153
J Biol Chem. 1995 Oct 27;270(43):25752-61
7592757
Am J Respir Crit Care Med. 2006 May 1;173(9):1008-15
16456142
Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R7-28
12069927
Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
12406830
Am J Respir Crit Care Med. 2002 May 15;165(10):1445-50
12016110
Virology. 2009 Sep 1;391(2):265-73
19592063
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7
15731496
Diabetes. 2004 Mar;53(3):743-51
14988260
Infection. 1991 Nov-Dec;19(6):447-52
1816119
Arthritis Rheum. 2006 Dec;54(12):3898-907
17133598
J Immunol. 2005 Nov 15;175(10):6764-71
16272333